DBP B Stock Overview
A pharmaceutical company, engages in the development and commercialization of approaches for the treatment of oncological, infectious, autoimmune, and other life-threatening diseases.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Double Bond Pharmaceutical International AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr0.50 |
52 Week High | kr2.00 |
52 Week Low | kr0.25 |
Beta | 0.69 |
1 Month Change | -20.89% |
3 Month Change | -29.97% |
1 Year Change | 25.00% |
3 Year Change | -67.74% |
5 Year Change | -89.58% |
Change since IPO | -88.89% |
Recent News & Updates
Recent updates
Shareholder Returns
DBP B | SE Pharmaceuticals | SE Market | |
---|---|---|---|
7D | -20.4% | 12.9% | -0.9% |
1Y | 25.0% | 83.0% | 14.3% |
Return vs Industry: DBP B underperformed the Swedish Pharmaceuticals industry which returned 83% over the past year.
Return vs Market: DBP B exceeded the Swedish Market which returned 14.3% over the past year.
Price Volatility
DBP B volatility | |
---|---|
DBP B Average Weekly Movement | 15.9% |
Pharmaceuticals Industry Average Movement | 9.3% |
Market Average Movement | 5.9% |
10% most volatile stocks in SE Market | 12.9% |
10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: DBP B's share price has been volatile over the past 3 months.
Volatility Over Time: DBP B's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2014 | 10 | Igor Lokot | www.doublebp.com |
Double Bond Pharmaceutical International AB (publ), a pharmaceutical company, engages in the development and commercialization of approaches for the treatment of oncological, infectious, autoimmune, and other life-threatening diseases. It offers Temodex, a therapy to treat malignant brain tumors; and SA033, a therapy to treat cancers in liver. The company is also developing Belopenem for the treatment of bacterial pneumonia.
Double Bond Pharmaceutical International AB (publ) Fundamentals Summary
DBP B fundamental statistics | |
---|---|
Market cap | kr51.01m |
Earnings (TTM) | -kr16.07m |
Revenue (TTM) | kr1.49m |
34.2x
P/S Ratio-3.2x
P/E RatioIs DBP B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
DBP B income statement (TTM) | |
---|---|
Revenue | kr1.49m |
Cost of Revenue | kr3.14m |
Gross Profit | -kr1.65m |
Other Expenses | kr14.42m |
Earnings | -kr16.07m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.16 |
Gross Margin | -110.80% |
Net Profit Margin | -1,078.01% |
Debt/Equity Ratio | 0% |
How did DBP B perform over the long term?
See historical performance and comparison